GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

Medically reviewed by Femi Aremu, PharmD Inflammation is a normal part of the body's immune response to pain, injury, or ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit in patients with inflammatory bowel disease (IBD). Evidence Rating Level: ...

A new study finds no significant differences in cardiovascular and thromboembolic risks among biologics for psoriasis or ...

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...

One reason is the fact that much research related to ovarian cancer has focused on strategies combining chemotherapy with ...

SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with ...

Lilly has also submitted marketing applications for Mirikizumab-mrkz in Crohn’s disease around the globe, including in the ...

If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.